MORPHOSYS TO DEVELOP ANTIBODIES FOR CENTOCOR

German biotech firm MorphoSys (MORG.DE: Quote, Profile, Research) said on Tuesday it will develop antibodies for a new target molecule for Centocor Inc., a Johnson & Johnson (JNJ.N: Quote, Profile, Research) company. MorphoSys, which entered into a collaboration with Centocor in 2000 to develop antibodies for a wide range of indications, said Centocor will carry out pre-clinical and clinical development and the subsequent marketing of resulting products.

Reuters (http://today.reuters.com/investing/financeArticle.aspx?type=mergersNews&storyID=2005-09-06T090559Z_01_L06321547_RTRIDST_0_HEALTH-MORPHOSYS-UPDATE-1.XML)